Loading…
Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid β-peptide
Abstract Amyloid β-peptide (Aβ) is a key molecule in Alzheimer's disease (AD). Reliable immunohistochemical (IHC) methods to detect Aβ and Aβ-associated factors (AAF) in brain specimens are needed to determine their role in AD pathophysiology. Formic acid (FA) pre-treatment, which is generally...
Saved in:
Published in: | Amyloid 2013-09, Vol.20 (3), p.179-187 |
---|---|
Main Authors: | , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c418t-88693d1fdb5b625c34c0ffa9ee88033a7f6e0dfcac2231df6f8d01fc2420d9483 |
---|---|
cites | cdi_FETCH-LOGICAL-c418t-88693d1fdb5b625c34c0ffa9ee88033a7f6e0dfcac2231df6f8d01fc2420d9483 |
container_end_page | 187 |
container_issue | 3 |
container_start_page | 179 |
container_title | Amyloid |
container_volume | 20 |
creator | Verwey, Nicolaas A. Hoozemans, Jeroen J.M. Korth, Carsten van Royen, Marloes R. Prikulis, Ingrid Wouters, Dorine Twaalfhoven, Harry A.M. van Haastert, Elise S. Schenk, Dale Scheltens, Philip Rozemuller, Annemieke J.M. Blankenstein, Marinus A. Veerhuis, Robert |
description | Abstract
Amyloid β-peptide (Aβ) is a key molecule in Alzheimer's disease (AD). Reliable immunohistochemical (IHC) methods to detect Aβ and Aβ-associated factors (AAF) in brain specimens are needed to determine their role in AD pathophysiology. Formic acid (FA) pre-treatment, which is generally used to enable efficient detection of Aβ with IHC, induces structural modifications within the Aβ, as well as in AAF. Consequently, interpretation of double IHC stainings becomes difficult. Therefore, serial stainings of two newly produced monoclonal antibodies (mAbs) VU-17 and IC16 and two other mAbs (6E10 and 3D6) were performed with four different pre-treatments (no pre-treatment, Tris/EDTA, citrate and FA) and additionally six IHC characteristics were scored: diffuse/compact/classic plaques, arteries with cerebral Aβ angiopathy, dyshoric angiopathy, capillaries with dyshoric angiopathy. Subsequently, these stainings were compared with IHC procedures, which are frequently used in a diagnostic setting, employing mAbs 4G8 and 6F/3D with FA pre-treatment. IHC Aβ patterns obtained with VU-17 and, IC16 and 3D6 without the use of FA pre-treatment were comparable to those obtained with 4G8 and 6F/3D upon FA pre-treatment. Omission of FA pre-treatment gives the advantage to allow double IHC stainings, detecting both Aβ and AAF that otherwise would have been structural modificated upon FA pre-treatment. |
doi_str_mv | 10.3109/13506129.2013.797389 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_23829200</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1427743278</sourcerecordid><originalsourceid>FETCH-LOGICAL-c418t-88693d1fdb5b625c34c0ffa9ee88033a7f6e0dfcac2231df6f8d01fc2420d9483</originalsourceid><addsrcrecordid>eNp9kctu1TAURS0Eog_4A4QyZJKLXzexJyBUQalUwQTG1rl-EFd-BNsBlc_iQ_gmEt0WiUlHx4O19zlaRugFwTtGsHxN2B4PhModxYTtRjkyIR-hUzJy3lNBxOP1vSL9xpygs1pvMKYMS_EUnVAmqKQYn6L5KsYl5cnXlvVko9cQOj1BAd1s8b-g-Zy67LqUf9jQxZyyDjmtEKTmD9l4Wzv4Bj7V1rXJdp_6NRd9WuqWgngbsjfdn9_9bOfmjX2GnjgI1T6_m-fo64f3Xy4-9tefL68u3l33mhPReiEGyQxx5rA_DHSvGdfYOZDWCoEZg9ENFhunQVPKiHGDEwYTpymn2Egu2Dl6deydS_6-2NpU9FXbECDZvFRFOB1Hzui4ofyI6pJrLdapufgI5VYRrDbX6t612lyro-s19vJuw3KI1vwL3ctdgbdHwCeXS4SfuQSjGqxKiiuQtK9b_YMr3vzXMFkIbdJQrLrJS1m_oT5841-PC6TE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1427743278</pqid></control><display><type>article</type><title>Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid β-peptide</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Verwey, Nicolaas A. ; Hoozemans, Jeroen J.M. ; Korth, Carsten ; van Royen, Marloes R. ; Prikulis, Ingrid ; Wouters, Dorine ; Twaalfhoven, Harry A.M. ; van Haastert, Elise S. ; Schenk, Dale ; Scheltens, Philip ; Rozemuller, Annemieke J.M. ; Blankenstein, Marinus A. ; Veerhuis, Robert</creator><creatorcontrib>Verwey, Nicolaas A. ; Hoozemans, Jeroen J.M. ; Korth, Carsten ; van Royen, Marloes R. ; Prikulis, Ingrid ; Wouters, Dorine ; Twaalfhoven, Harry A.M. ; van Haastert, Elise S. ; Schenk, Dale ; Scheltens, Philip ; Rozemuller, Annemieke J.M. ; Blankenstein, Marinus A. ; Veerhuis, Robert</creatorcontrib><description>Abstract
Amyloid β-peptide (Aβ) is a key molecule in Alzheimer's disease (AD). Reliable immunohistochemical (IHC) methods to detect Aβ and Aβ-associated factors (AAF) in brain specimens are needed to determine their role in AD pathophysiology. Formic acid (FA) pre-treatment, which is generally used to enable efficient detection of Aβ with IHC, induces structural modifications within the Aβ, as well as in AAF. Consequently, interpretation of double IHC stainings becomes difficult. Therefore, serial stainings of two newly produced monoclonal antibodies (mAbs) VU-17 and IC16 and two other mAbs (6E10 and 3D6) were performed with four different pre-treatments (no pre-treatment, Tris/EDTA, citrate and FA) and additionally six IHC characteristics were scored: diffuse/compact/classic plaques, arteries with cerebral Aβ angiopathy, dyshoric angiopathy, capillaries with dyshoric angiopathy. Subsequently, these stainings were compared with IHC procedures, which are frequently used in a diagnostic setting, employing mAbs 4G8 and 6F/3D with FA pre-treatment. IHC Aβ patterns obtained with VU-17 and, IC16 and 3D6 without the use of FA pre-treatment were comparable to those obtained with 4G8 and 6F/3D upon FA pre-treatment. Omission of FA pre-treatment gives the advantage to allow double IHC stainings, detecting both Aβ and AAF that otherwise would have been structural modificated upon FA pre-treatment.</description><identifier>ISSN: 1350-6129</identifier><identifier>EISSN: 1744-2818</identifier><identifier>DOI: 10.3109/13506129.2013.797389</identifier><identifier>PMID: 23829200</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Alzheimer Disease - diagnosis ; Alzheimer Disease - metabolism ; Alzheimer Disease - pathology ; Alzheimers disease ; Amyloid beta-Peptides - analysis ; Amyloid beta-Peptides - chemistry ; Amyloid beta-Peptides - immunology ; amyloidosis ; Animals ; Antibodies, Monoclonal - biosynthesis ; brain tissue ; Capillaries - metabolism ; Capillaries - pathology ; Cerebral Amyloid Angiopathy - diagnosis ; Cerebral Amyloid Angiopathy - metabolism ; Cerebral Amyloid Angiopathy - pathology ; dementia ; Formates - chemistry ; Humans ; Hybridomas - immunology ; Immunohistochemistry ; Mice ; Plaque, Amyloid - diagnosis ; Plaque, Amyloid - metabolism ; Plaque, Amyloid - pathology ; Protein Structure, Tertiary ; Sensitivity and Specificity</subject><ispartof>Amyloid, 2013-09, Vol.20 (3), p.179-187</ispartof><rights>2013 Informa UK Ltd. All rights reserved: reproduction in whole or part not permitted 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c418t-88693d1fdb5b625c34c0ffa9ee88033a7f6e0dfcac2231df6f8d01fc2420d9483</citedby><cites>FETCH-LOGICAL-c418t-88693d1fdb5b625c34c0ffa9ee88033a7f6e0dfcac2231df6f8d01fc2420d9483</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23829200$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Verwey, Nicolaas A.</creatorcontrib><creatorcontrib>Hoozemans, Jeroen J.M.</creatorcontrib><creatorcontrib>Korth, Carsten</creatorcontrib><creatorcontrib>van Royen, Marloes R.</creatorcontrib><creatorcontrib>Prikulis, Ingrid</creatorcontrib><creatorcontrib>Wouters, Dorine</creatorcontrib><creatorcontrib>Twaalfhoven, Harry A.M.</creatorcontrib><creatorcontrib>van Haastert, Elise S.</creatorcontrib><creatorcontrib>Schenk, Dale</creatorcontrib><creatorcontrib>Scheltens, Philip</creatorcontrib><creatorcontrib>Rozemuller, Annemieke J.M.</creatorcontrib><creatorcontrib>Blankenstein, Marinus A.</creatorcontrib><creatorcontrib>Veerhuis, Robert</creatorcontrib><title>Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid β-peptide</title><title>Amyloid</title><addtitle>Amyloid</addtitle><description>Abstract
Amyloid β-peptide (Aβ) is a key molecule in Alzheimer's disease (AD). Reliable immunohistochemical (IHC) methods to detect Aβ and Aβ-associated factors (AAF) in brain specimens are needed to determine their role in AD pathophysiology. Formic acid (FA) pre-treatment, which is generally used to enable efficient detection of Aβ with IHC, induces structural modifications within the Aβ, as well as in AAF. Consequently, interpretation of double IHC stainings becomes difficult. Therefore, serial stainings of two newly produced monoclonal antibodies (mAbs) VU-17 and IC16 and two other mAbs (6E10 and 3D6) were performed with four different pre-treatments (no pre-treatment, Tris/EDTA, citrate and FA) and additionally six IHC characteristics were scored: diffuse/compact/classic plaques, arteries with cerebral Aβ angiopathy, dyshoric angiopathy, capillaries with dyshoric angiopathy. Subsequently, these stainings were compared with IHC procedures, which are frequently used in a diagnostic setting, employing mAbs 4G8 and 6F/3D with FA pre-treatment. IHC Aβ patterns obtained with VU-17 and, IC16 and 3D6 without the use of FA pre-treatment were comparable to those obtained with 4G8 and 6F/3D upon FA pre-treatment. Omission of FA pre-treatment gives the advantage to allow double IHC stainings, detecting both Aβ and AAF that otherwise would have been structural modificated upon FA pre-treatment.</description><subject>Alzheimer Disease - diagnosis</subject><subject>Alzheimer Disease - metabolism</subject><subject>Alzheimer Disease - pathology</subject><subject>Alzheimers disease</subject><subject>Amyloid beta-Peptides - analysis</subject><subject>Amyloid beta-Peptides - chemistry</subject><subject>Amyloid beta-Peptides - immunology</subject><subject>amyloidosis</subject><subject>Animals</subject><subject>Antibodies, Monoclonal - biosynthesis</subject><subject>brain tissue</subject><subject>Capillaries - metabolism</subject><subject>Capillaries - pathology</subject><subject>Cerebral Amyloid Angiopathy - diagnosis</subject><subject>Cerebral Amyloid Angiopathy - metabolism</subject><subject>Cerebral Amyloid Angiopathy - pathology</subject><subject>dementia</subject><subject>Formates - chemistry</subject><subject>Humans</subject><subject>Hybridomas - immunology</subject><subject>Immunohistochemistry</subject><subject>Mice</subject><subject>Plaque, Amyloid - diagnosis</subject><subject>Plaque, Amyloid - metabolism</subject><subject>Plaque, Amyloid - pathology</subject><subject>Protein Structure, Tertiary</subject><subject>Sensitivity and Specificity</subject><issn>1350-6129</issn><issn>1744-2818</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNp9kctu1TAURS0Eog_4A4QyZJKLXzexJyBUQalUwQTG1rl-EFd-BNsBlc_iQ_gmEt0WiUlHx4O19zlaRugFwTtGsHxN2B4PhModxYTtRjkyIR-hUzJy3lNBxOP1vSL9xpygs1pvMKYMS_EUnVAmqKQYn6L5KsYl5cnXlvVko9cQOj1BAd1s8b-g-Zy67LqUf9jQxZyyDjmtEKTmD9l4Wzv4Bj7V1rXJdp_6NRd9WuqWgngbsjfdn9_9bOfmjX2GnjgI1T6_m-fo64f3Xy4-9tefL68u3l33mhPReiEGyQxx5rA_DHSvGdfYOZDWCoEZg9ENFhunQVPKiHGDEwYTpymn2Egu2Dl6deydS_6-2NpU9FXbECDZvFRFOB1Hzui4ofyI6pJrLdapufgI5VYRrDbX6t612lyro-s19vJuw3KI1vwL3ctdgbdHwCeXS4SfuQSjGqxKiiuQtK9b_YMr3vzXMFkIbdJQrLrJS1m_oT5841-PC6TE</recordid><startdate>201309</startdate><enddate>201309</enddate><creator>Verwey, Nicolaas A.</creator><creator>Hoozemans, Jeroen J.M.</creator><creator>Korth, Carsten</creator><creator>van Royen, Marloes R.</creator><creator>Prikulis, Ingrid</creator><creator>Wouters, Dorine</creator><creator>Twaalfhoven, Harry A.M.</creator><creator>van Haastert, Elise S.</creator><creator>Schenk, Dale</creator><creator>Scheltens, Philip</creator><creator>Rozemuller, Annemieke J.M.</creator><creator>Blankenstein, Marinus A.</creator><creator>Veerhuis, Robert</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201309</creationdate><title>Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid β-peptide</title><author>Verwey, Nicolaas A. ; Hoozemans, Jeroen J.M. ; Korth, Carsten ; van Royen, Marloes R. ; Prikulis, Ingrid ; Wouters, Dorine ; Twaalfhoven, Harry A.M. ; van Haastert, Elise S. ; Schenk, Dale ; Scheltens, Philip ; Rozemuller, Annemieke J.M. ; Blankenstein, Marinus A. ; Veerhuis, Robert</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c418t-88693d1fdb5b625c34c0ffa9ee88033a7f6e0dfcac2231df6f8d01fc2420d9483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Alzheimer Disease - diagnosis</topic><topic>Alzheimer Disease - metabolism</topic><topic>Alzheimer Disease - pathology</topic><topic>Alzheimers disease</topic><topic>Amyloid beta-Peptides - analysis</topic><topic>Amyloid beta-Peptides - chemistry</topic><topic>Amyloid beta-Peptides - immunology</topic><topic>amyloidosis</topic><topic>Animals</topic><topic>Antibodies, Monoclonal - biosynthesis</topic><topic>brain tissue</topic><topic>Capillaries - metabolism</topic><topic>Capillaries - pathology</topic><topic>Cerebral Amyloid Angiopathy - diagnosis</topic><topic>Cerebral Amyloid Angiopathy - metabolism</topic><topic>Cerebral Amyloid Angiopathy - pathology</topic><topic>dementia</topic><topic>Formates - chemistry</topic><topic>Humans</topic><topic>Hybridomas - immunology</topic><topic>Immunohistochemistry</topic><topic>Mice</topic><topic>Plaque, Amyloid - diagnosis</topic><topic>Plaque, Amyloid - metabolism</topic><topic>Plaque, Amyloid - pathology</topic><topic>Protein Structure, Tertiary</topic><topic>Sensitivity and Specificity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Verwey, Nicolaas A.</creatorcontrib><creatorcontrib>Hoozemans, Jeroen J.M.</creatorcontrib><creatorcontrib>Korth, Carsten</creatorcontrib><creatorcontrib>van Royen, Marloes R.</creatorcontrib><creatorcontrib>Prikulis, Ingrid</creatorcontrib><creatorcontrib>Wouters, Dorine</creatorcontrib><creatorcontrib>Twaalfhoven, Harry A.M.</creatorcontrib><creatorcontrib>van Haastert, Elise S.</creatorcontrib><creatorcontrib>Schenk, Dale</creatorcontrib><creatorcontrib>Scheltens, Philip</creatorcontrib><creatorcontrib>Rozemuller, Annemieke J.M.</creatorcontrib><creatorcontrib>Blankenstein, Marinus A.</creatorcontrib><creatorcontrib>Veerhuis, Robert</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Amyloid</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Verwey, Nicolaas A.</au><au>Hoozemans, Jeroen J.M.</au><au>Korth, Carsten</au><au>van Royen, Marloes R.</au><au>Prikulis, Ingrid</au><au>Wouters, Dorine</au><au>Twaalfhoven, Harry A.M.</au><au>van Haastert, Elise S.</au><au>Schenk, Dale</au><au>Scheltens, Philip</au><au>Rozemuller, Annemieke J.M.</au><au>Blankenstein, Marinus A.</au><au>Veerhuis, Robert</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid β-peptide</atitle><jtitle>Amyloid</jtitle><addtitle>Amyloid</addtitle><date>2013-09</date><risdate>2013</risdate><volume>20</volume><issue>3</issue><spage>179</spage><epage>187</epage><pages>179-187</pages><issn>1350-6129</issn><eissn>1744-2818</eissn><abstract>Abstract
Amyloid β-peptide (Aβ) is a key molecule in Alzheimer's disease (AD). Reliable immunohistochemical (IHC) methods to detect Aβ and Aβ-associated factors (AAF) in brain specimens are needed to determine their role in AD pathophysiology. Formic acid (FA) pre-treatment, which is generally used to enable efficient detection of Aβ with IHC, induces structural modifications within the Aβ, as well as in AAF. Consequently, interpretation of double IHC stainings becomes difficult. Therefore, serial stainings of two newly produced monoclonal antibodies (mAbs) VU-17 and IC16 and two other mAbs (6E10 and 3D6) were performed with four different pre-treatments (no pre-treatment, Tris/EDTA, citrate and FA) and additionally six IHC characteristics were scored: diffuse/compact/classic plaques, arteries with cerebral Aβ angiopathy, dyshoric angiopathy, capillaries with dyshoric angiopathy. Subsequently, these stainings were compared with IHC procedures, which are frequently used in a diagnostic setting, employing mAbs 4G8 and 6F/3D with FA pre-treatment. IHC Aβ patterns obtained with VU-17 and, IC16 and 3D6 without the use of FA pre-treatment were comparable to those obtained with 4G8 and 6F/3D upon FA pre-treatment. Omission of FA pre-treatment gives the advantage to allow double IHC stainings, detecting both Aβ and AAF that otherwise would have been structural modificated upon FA pre-treatment.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>23829200</pmid><doi>10.3109/13506129.2013.797389</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1350-6129 |
ispartof | Amyloid, 2013-09, Vol.20 (3), p.179-187 |
issn | 1350-6129 1744-2818 |
language | eng |
recordid | cdi_pubmed_primary_23829200 |
source | Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list) |
subjects | Alzheimer Disease - diagnosis Alzheimer Disease - metabolism Alzheimer Disease - pathology Alzheimers disease Amyloid beta-Peptides - analysis Amyloid beta-Peptides - chemistry Amyloid beta-Peptides - immunology amyloidosis Animals Antibodies, Monoclonal - biosynthesis brain tissue Capillaries - metabolism Capillaries - pathology Cerebral Amyloid Angiopathy - diagnosis Cerebral Amyloid Angiopathy - metabolism Cerebral Amyloid Angiopathy - pathology dementia Formates - chemistry Humans Hybridomas - immunology Immunohistochemistry Mice Plaque, Amyloid - diagnosis Plaque, Amyloid - metabolism Plaque, Amyloid - pathology Protein Structure, Tertiary Sensitivity and Specificity |
title | Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid β-peptide |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T13%3A20%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunohistochemical%20characterization%20of%20novel%20monoclonal%20antibodies%20against%20the%20N-terminus%20of%20amyloid%20%CE%B2-peptide&rft.jtitle=Amyloid&rft.au=Verwey,%20Nicolaas%20A.&rft.date=2013-09&rft.volume=20&rft.issue=3&rft.spage=179&rft.epage=187&rft.pages=179-187&rft.issn=1350-6129&rft.eissn=1744-2818&rft_id=info:doi/10.3109/13506129.2013.797389&rft_dat=%3Cproquest_pubme%3E1427743278%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c418t-88693d1fdb5b625c34c0ffa9ee88033a7f6e0dfcac2231df6f8d01fc2420d9483%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1427743278&rft_id=info:pmid/23829200&rfr_iscdi=true |